// App-Quantinova.ai

P719 : EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB-ANALYSIS FROM THE PHASE 4 BYOND TRIAL

Researchers

Presenter

  • Carlo Gambacorti-Passerini

Principal Investigators

  • Tim H. Brmmendorf

  • Thomas Ernst

  • Eric Leip

  • Simon Purcell

  • Andrea Viqueira

  • Francis J. Giles

  • Gianantonio Rosti

  • Andreas Hochhaus

Medical Centers

  • Klinik fur Innere Medizin II, Universitatsklinikum Jena, Jena, Germany

  • Klinik fur Innere Medizin II, Universitatsklinikum Jena, Jena, Germany

  • Pfizer SLU,Madrid,Spanje

  • Pfizer SLU,Madrid,Испания

  • Pfizer Ltd, London, United Kingdom

  • Pfizer SLU,Madrid,Spanje

  • Univer

  • Pfizer Inc., Cambridge, MA

  • Pfizer Inc,Cambridge,États-unis

  • Pfizer SLU,Madrid,Espanha

  • Universitätsklinikum RWTH Aachen,Aachen,Alemania

  • Developmental Therapeutics Consortium,Chicago,Vereinigte Staaten

  • University of Milano-Bicocca, Monza, Italy

  • Pfizer Ltd,London,Verenigd Koninkrijk

  • Universitätsklinikum RWTH Aachen,Aachen,Alemania

  • University of Milano-Bicocca, Monza, Italy

  • Universitätsklinikum RWTH Aachen,Aachen,Allemagne

  • Klinik fur Innere Medizin II, Universitatsklinikum Jena, Jena, Germany

  • Pfizer Ltd,London,Storbritannien

  • University of Milano-Bicocca, Monza, Italy

  • Pfizer Inc,Cambridge,Verenigde Staten

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (I

  • Klinik fur Innere Medizin II, Universitatsklinikum Jena, Jena, Germany

  • Developmental Therapeutics Consortium, Chicago, IL

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy

  • University of Milano-Bicocca, Monza, Italy

  • Pfizer Ltd,London,Vereinigtes Königreich

  • Universitätsklinikum RWTH Aachen,Aachen,Alemania

  • Klinik für Innere Medizin II, Universitätsklini

  • Epizyme, Inc.,Cambridge,Estados Unidos

  • Pfizer SLU,Madrid,Spanje

  • Pfizer SLU,Madrid,Spanje

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy

  • Universitätsklinikum RWTH Aachen,Aachen,Allemagne

  • Klinik fur Innere Medizin II, Universitatsklinikum Jena, Jena, Germany

  • Pfizer Ltd,London,Соединённое Королевство

  • Developmental Therapeutics Consortiu

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Pfizer Spain, Madrid, Spain

  • University of Milano-Bicocca, Monza, Italy

  • Developmental Therapeutics Consortium, Chicago, IL

  • Developmental Therapeutics Consortium,Chicago,Vereinigte Staaten

  • Pfizer SLU,Madrid,Espanha

  • Pfizer Ltd,London,Royaume-uni

  • University of Milano-Bicocca, Monza, Italy

  • University of Milano-Bicocca,Monza,Италия

  • Developmental Therapeutics Consortium,Chicago,Estados Unidos

  • Developmental Therapeutics Consortium,Chicago,Vereinigte Staaten

  • Pfizer Ltd,London,Regno Unito

  • Pfizer Inc.,Cambridge,Stati Uniti

  • Pfizer Inc,Cambridge,United States

  • Pfizer Ltd,London,Regno Unito

  • Universitätsklinikum RWTH Aachen,Aachen,Германия

  • Pfizer Inc,Cambridge,Verenigde Staten

  • Universitätsklinikum RWTH Aachen,Aachen,Allemagne

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy

Locations

  • Italy

  • Germany

  • United States

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Bosutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • IV

Study Id's

  • NCT02228382

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved